Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400094 | 0.82 | HRH3 (0.47) | HRH3HRH1 | |
| SCHEMBL4391275 | 0.81 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL4400291 | 0.81 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL4395454 | 0.81 | HRH3 (0.65) | HRH3HRH1 | |
| SCHEMBL4128624 | 0.70 | FAAH (0.44) | HRH3 | |
| SCHEMBL4142184 | 0.70 | FAAH (0.44) | HRH3 | |
| SCHEMBL4128623 | 0.70 | FAAH (0.44) | HRH3 | |
| SCHEMBL4145589 | 0.70 | FAAH (0.44) | HRH3 | |
| SCHEMBL4287122 | 0.70 | FAAH (0.44) | HRH3 | |
| SCHEMBL4133345 | 0.70 | FAAH (0.44) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | claimed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| EP-1833796-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006061193-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, INMT, INA | HRH3 2097/4885HRH1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.